VolitionRx (NYSE:VNRX) Now Covered by Analysts at StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of VolitionRx (NYSE:VNRX) in a note issued to investors on Wednesday. The firm set a “sell” rating on the stock.

Separately, Benchmark reissued a “hold” rating on shares of VolitionRx in a research note on Friday, August 16th.

VolitionRx Stock Up 4.0 %

Shares of VolitionRx stock opened at $0.69 on Wednesday. VolitionRx has a 52 week low of $0.43 and a 52 week high of $1.23. The stock’s 50-day simple moving average is $0.68 and its 200-day simple moving average is $0.68. The company has a market capitalization of $63.94 million, a price-to-earnings ratio of -1.92 and a beta of 1.10.

Hedge Funds Weigh In On VolitionRx

An institutional investor recently raised its position in VolitionRx stock. Ground Swell Capital LLC increased its stake in VolitionRx Limited (NYSE:VNRX) by 78.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 45,959 shares of the company’s stock after buying an additional 20,249 shares during the quarter. Ground Swell Capital LLC’s holdings in VolitionRx were worth $28,000 as of its most recent SEC filing. 8.09% of the stock is currently owned by institutional investors.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.